About OptiNose
OptiNose is a company based in Morrisville (United States) founded in 2000 was acquired by Paratek Pharma in March 2025. OptiNose has raised $120.5 million across 10 funding rounds from investors including Fidelity Investments, Paratek Pharma and bpcruk. The company has 132 employees as of December 31, 2023. OptiNose offers products and services including XHANCE, ONZETRA, and Xsail. OptiNose operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
- Headquarter Morrisville, United States
- Employees 132 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Optinose Us, Inc.
-
Annual Revenue
$76.28 M (USD)2as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$120.5 M (USD)
in 10 rounds
-
Latest Funding Round
$4.68 M (USD), Post-IPO
May 10, 2024
-
Investors
Fidelity Investments
& 6 more
-
Employee Count
132
as on Dec 31, 2023
-
Acquired by
Paratek Pharma
(Mar 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OptiNose
OptiNose offers a comprehensive portfolio of products and services, including XHANCE, ONZETRA, and Xsail.
Delivers steroid for treating nasal inflammation in ENT conditions.
Exhalation delivery system for migraine relief medication.
Nasal device for effective medication administration in allergies.
People of OptiNose
Unlock access to complete
Funding Insights of OptiNose
OptiNose has successfully raised a total of $120.5M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.68 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OptiNose
OptiNose has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paratek Pharma and bpcruk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Tech & life science focused stage agnostic VC firm investing primarily in Western Europe
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for OptiNose
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OptiNose
Investment portfolio details for OptiNose
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OptiNose
Detailed financials for OptiNose
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Optinose Comparisons
Peer comparison for OptiNose
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OptiNose
OptiNose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, Qnovia and Iconovo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Intranasal delivery technology for CNS diseases is developed.
|
|
| Locked | Locked | Locked |
Developer of products for the treatment of acute and intermittent conditions
|
|
| Locked | Locked | Locked |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Inhalation devices for medical applications are developed by Iconovo.
|
Detailed competitors of OptiNose
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Optinose
Complete news archive for OptiNose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OptiNose
OptiNose was founded in 2000 and raised its 1st funding round 10 years after it was founded.
OptiNose is headquartered in Morrisville, United States.
OptiNose is a funded company, having raised a total of $120.5M across 10 funding rounds to date.
As of Dec 31, 2023, the latest employee count at OptiNose is 132.
Annual revenue of OptiNose is $76.28M as on Dec 31, 2022.
OptiNose is a developer of smart devices for nasal drug delivery. The drug delivery devices can be used for powder and liquid formulations. Pipeline includes candidates for chronic nasal inflammatory disease, migraine and autism.
OptiNose's top competitors include MannKind Corp, Impel NeuroPharma and Qnovia.
OptiNose offers XHANCE, ONZETRA, and Xsail.
OptiNose has 7 investors. Key investors include Fidelity Investments, Paratek Pharma, bpcruk, Athyrium Capital Management, and Avista Capital Partners.